← All Esperion Therapeutics, INC filings

Esperion Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ESPR
Esperion Therapeutics, INC
10-K: Esperion Therapeutics Reports Positive 2024 Results, Navigates Debt Restructuring
Esperion Therapeutics highlights FDA label expansions, strategic collaborations, and financial maneuvers in its 2024 annual report, aiming for sustained growth in the LDL-C and cardiovascular risk reduction market.
NASDAQ
ESPR
Esperion Therapeutics, INC
10-K: Esperion Therapeutics 10-K Filing: Details on Securities, Risks, and Future Outlook
Esperion Therapeutics' 10-K filing outlines the company's stock structure, potential risks, and strategic focus on commercializing its cholesterol-lowering drugs.